What should we do about screening for genital chlamydia? by Low, Nicola & Egger, Matthias
International Journal of Epidemiology 2002;31:891–893
Chlamydia trachomatis is the world’s most common bacterial
sexually transmitted infection, with an estimated 89 million
new cases each year.1 Genital chlamydia poses a major global
public health problem because it is a transmissible cause of
severe reproductive morbidity, including pelvic inflammatory
disease, impaired fertility and ectopic pregnancy in women.2
Chlamydia can be cured with antibiotics and transmission
prevented by treating sexual partners, but most infections are
asymptomatic so they remain undiagnosed. Early diagnosis is
possible, with DNA amplification techniques now providing
highly sensitive and specific tests3 that are more acceptable to
patients than previous methods because they can be performed
on non-invasively collected genital specimens. Probably more
than any other single factor, these technological advances in
chlamydial diagnosis are driving the current health policy
debate about the introduction of national chlamydia screening
programmes.4,5 But do we have enough evidence about the
effectiveness of screening and about the natural history of
chlamydial disease to be sure that proposed screening pro-
grammes will be the most effective and cost-effective way of
preventing the long term consequences of infection?
The appropriateness of screening for disease prevention is
usually assessed according to principles set out by Wilson and
Jungner in 1966.6 These criteria have been expanded by policy-
making bodies such as the UK National Screening Committee to
emphasize the rigorous standards of research evidence required
to demonstrate effectiveness and the programme aspects of
screening.7 Genital chlamydia has been judged to fulfil these
criteria either in whole,8,9 or in part.4,10 So how strong is the
evidence? The first randomized trial evaluated the effect of
chlamydia screening on the incidence of pelvic inflammatory
disease in women in a health maintenance organization ful-
filling criteria for being at high risk of infection.11 This approach
would be classified as a selective population screening strategy.
The incidence of pelvic inflammatory disease at one year was
56% (95% CI: 10–80%) lower in the intervention than the
control group. The potential for bias introduced by the study
design, however, makes the results difficult to interpret.10,12,13
In particular, randomization was performed before women were
invited for screening, and those allocated to the screening arm
were more vigorously recruited.11 Thus, of more than 36 000
women randomized to intervention and control groups in a
ratio of 1:2, only 2607 (7.1%) were included in the analysis,
with the ratio of intervention to control groups falling to 1:1.6.
More recently, randomized trials in Denmark have also evalu-
ated population screening, inviting school students14 and young
people in the general population15 to submit self-taken urine or
vaginal specimens for chlamydia testing. Amongst women in the
school-based study the incidence of pelvic inflammatory disease
at one year was reduced by 50%.14 Over 45% of study partici-
pants were, however, lost to follow-up in this study. Whilst
evidence from randomized trials is essential, problems with trial
quality that could bias the estimated benefits of chlamydia
screening could lead to future challenges and debate about the
justification for screening programmes, as has recently happened
with breast cancer screening.16–18 Furthermore, the randomized
trials evaluated population-based approaches to screening but
they have also been cited as evidence in support of opportun-
istic screening of people using existing health services.8,19 It is
unclear to what extent the results of population-based screening
can be extrapolated to opportunistic strategies.
Observational data from chlamydia screening programmes
established before randomized trials were performed also
provide evidence that screening is associated with reductions in
the prevalence of genital chlamydia, pelvic inflammatory
disease and ectopic pregnancy.20–22 Programmes were set up in
Sweden21 and parts of the US20 during the mid-1980s to
conduct opportunistic screening on unselected, mostly female,
populations attending a variety of health care settings. Five to 9
years after implementation, proportions of positive samples
tested by laboratories in these programmes had decreased by
one- to two-thirds.20,21 However, surveillance data from countries
with23 and without24 screening programmes have shown similar
recent increases in the prevalence of chlamydia (Figure). Changes
in population prevalence are clearly influenced by the number
of people being tested and, although this has increased in Sweden,
the proportion of positive tests has also increased from a nadir
of 4.1% in 1994 to 6.1% in 2000.23 These findings suggest that
the opportunistic screening approach to chlamydia control may
have reached its limit.
A potential explanation for the resurgence of chlamydia in
Sweden could be the failure to include men comprehensively in
the screening programme. Opportunistic programmes only
reach health service users, and amongst young sexually active
people, these are mostly women. In Sweden only 20–25% of
chlamydia specimens come from men.21 Control of chlamydia
transmission should occur through partner notification, which
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is compulsory in Sweden. It has also been widely assumed that
prevalence of chlamydia is lower in men than women because
of lower female to male transmission efficiency and because the
majority of infections in men were presumed to be symptomatic
and to present early for testing and treatment.25 Another
application of DNA amplification diagnostic techniques has shown
this assumption to be false. Several studies have now estimated
the prevalence of chlamydia in population-based samples using
non-invasive home-collected specimens.26–29 In the European
studies, chlamydia prevalence was 2.2–2.3% in men and 1.5–2.9%
in women.13,26,28 A smaller study from Baltimore found, in our
calculation, crude prevalence rates of 3.2% (95% CI: 0.1–7.9%)
and 5.2% (95% CI: 2.5–9.3%) in Black men and women, and
3.3% (95% CI: 0.1–8.5%) and 0% (upper CI: 2.6%) in men and
women of other ethnic groups.29 Together, these studies suggest
that the circulating pool of asymptomatic untreated chlamydia
may be similar in men and women. A strategy combining oppor-
tunistic screening in health care settings, which tends to miss a
large proportion of men at risk, and partner notification may
not be sufficient to produce sustained reductions in chlamydia
prevalence.
The case in favour of chlamydia screening for a range of
populations and screening strategies has also been made on the
grounds of cost-effectiveness.30–33 Most of the cost savings
achieved through screening come from the predicted costs of
treatment of complications avoided.32,34 Economic models are
highly sensitive to assumptions about the incidence of compli-
cations34 but these are notoriously difficult to measure. Studies
estimating the rate of progression from lower genital tract
chlamydia to pelvic inflammatory disease are hindered by small
sample size and a lack of objective diagnostic criteria for pelvic
inflammatory disease. The most widely cited study found pelvic
inflammatory disease in 6 of 20 women with chlamydia (30%,
95% CI: 12–54%).35 Uncertainty about, and especially over-
estimation of the incidence of complications, could give misleading
results about the cost-effectiveness of screening interventions.
Piecing together the natural history of chlamydial disease is
fraught with problems,2,10,34 not least because of the ethics of
studying the prognosis of untreated infection. The long term
outcomes of laparoscopically confirmed pelvic inflammatory
disease have been studied in cohort studies36,37 with up to 25 years
of follow-up.37 These studies are of limited use, however, because
they report only the proportions of women developing infertility
or ectopic pregnancy, without taking into account the
longitudinal nature of the data, losses to follow up over time or
confounding by contraceptive choice or sexual behaviour. Further-
more, in the largest study, chlamydia status at baseline was not
known.37
Ideally, individual or cluster randomized controlled trials in
which the potential for bias has been minimized should com-
pare the effect of different screening strategies with no screening
on the incidence of pelvic inflammatory disease and chlamydia.
A cluster trial is now being piloted in Scotland (Phil Wilson,
University of Glasgow, personal communication). Screening for
chlamydia in men also needs to be evaluated and methods of
including men in chlamydia screening programmes considered.
The ongoing Chlamydia Screening Studies (ClaSS) in the Avon
and West Midlands regions of England were set up to determine
the prevalence in the sexually active male and female popu-
lation and to examine the feasibility, acceptability and costs of a
mass screening programme. A similar project is ongoing in four
regional municipal health services in the Netherlands.38 Initial
results from the Chlamydia Pilot Studies in the Wirral and
Portsmouth, England, indicate that opportunistic screening is
feasible in a range of settings in the National Health Service, and
significant population coverage can be achieved.39 In order to
model more accurately the cost effectiveness of chlamydia screen-
ing programmes we also need to improve our understanding of
the natural history of chlamydial disease. A linkage study in
Uppsala, Sweden, where widespread opportunistic screening
was introduced in 1985, will provide information on the incidence
of sequelae in women who screened positive for chlamydia,
women who screened negative, and women who declined to
participate in the programme (Björn Herrmann, University of
Uppsala, personal communication). The results from a number
of ongoing studies will thus fill some of the important gaps in
the evidence base. Surely, in the UK and elsewhere, we should
avoid pressure to implement a screening programme prematurely
without being sure that this is the most sustainable approach to
controlling chlamydia and its reproductive consequences.
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